<SUBMISSION>
<ACCESSION-NUMBER>0000351721-00-000015
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>1
<PERIOD>20001201
<ITEMS>1
<FILING-DATE>20001201
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED NEUROMODULATION SYSTEMS INC
<CIK>0000351721
<ASSIGNED-SIC>3841
<IRS-NUMBER>751646002
<STATE-OF-INCORPORATION>TX
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-10521
<FILM-NUMBER>781884
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6501 WINDCREST DRIVE SUITE 100
<CITY>PLANO
<STATE>TX
<ZIP>75024
<PHONE>9723098000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6501 WINDCREST DRIVE SUITE 100
<CITY>PLANO
<STATE>TX
<ZIP>75024
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>QUEST MEDICAL INC
<DATE-CHANGED>19920703
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>0001.htm
<DESCRIPTION>FORM 8-K
<TEXT>

<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY>

<H1 ALIGN=CENTER><FONT SIZE=3>SECURITIES AND EXCHANGE COMMISSION</FONT></H1>
<H1 ALIGN=CENTER><FONT SIZE=3>Washington, D.C. 20549</FONT></H1>
<HR SIZE=1 WIDTH=15% ALIGN=CENTER>
<H1 ALIGN=CENTER><FONT SIZE=4>FORM 8-K</FONT></H1>
<HR SIZE=1 WIDTH=15% ALIGN=CENTER>
<H1 ALIGN=CENTER><FONT SIZE=3>CURRENT REPORT<BR>PURSUANT TO SECTION 13 OR 15(d)
OF THE<BR>SECURITIES EXCHANGE ACT OF 1934</FONT></H1>
<H1 ALIGN=CENTER><FONT SIZE=3>Date of report (Date of earliest event reported):
<BR>December 1, 2000 (November 30, 2000)</FONT></H1>

<HR SIZE=1 WIDTH=15% ALIGN=CENTER>
<P ALIGN=CENTER><FONT SIZE=3>Commission file number 0-10521</FONT></P>
<H1 ALIGN=CENTER><FONT SIZE=4>ADVANCED NEUROMODULATION SYSTEMS, INC.</FONT></H1>
<P ALIGN=CENTER><FONT SIZE=3>Incorporated pursuant to the Laws of the State of
Texas</FONT></P>
<HR SIZE=1 WIDTH=15% ALIGN=CENTER>
<P ALIGN=CENTER><FONT SIZE=3>Internal Revenue Service &#151; Employer
Identification No. 75-1646002</FONT></P>
<P ALIGN=CENTER><FONT SIZE=3>6501 Windcrest Drive, Plano, Texas 75024</FONT></P>
<P ALIGN=CENTER><FONT SIZE=3>(972) 309-8000</FONT></P>
<HR SIZE=1 WIDTH=15% ALIGN=CENTER>
<HR>
<P><B>Item 5.&nbsp;&nbsp;Other Events.</B></P>
<P>On November 30, 2000, the Registrant entered into an agreement to acquire
Hi-tronics Designs, Inc., a New Jersey corporation ("HDI"), through a merger
of ANS Acquisition Corp., a New Jersey corporation and wholly-owned direct
subsidiary of the Registrant, with and into HDI (the "Merger"), pursuant to
which the Registrant will issue approximately 1.1 million shares of its Common
Stock. The Registrant intends to account for this transaction using the pooling
of interests accounting method. For additional information, reference is made to
the press release attached hereto as Exhibit 99.1.</P>
<P><B>Item 7.&nbsp;&nbsp;Financial Statements, Pro Forma Financial Information
and Exhibits.</B></P>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR>
<TD WIDTH=7% ALIGN=LEFT>(c)</TD>
<TD WIDTH=93% ALIGN=LEFT>Exhibits</TD></TR>
<TR><TD>&nbsp;</TD><TD></TD></TR>
<TR>
<TD>99.1</TD>
<TD>Press Release dated December 1, 2000</TD>
</TABLE>
<HR>
<H1 ALIGN=CENTER><FONT SIZE=3><A NAME="Signatures">Signatures</A></FONT>
</H1><P><FONT SIZE=3>In accordance with the requirements of the Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P><TABLE>
<TR><TD WIDTH=40%></TD>
<TD WIDTH=60%>ADVANCED NEUROMODULATION SYSTEMS, INC.<BR><BR><BR></TD>
</TR><TR><TD WIDTH=40%></TD><TD WIDTH=60%>By: /s/ F. Robert Merrill III
<BR>----------------------------------</TD></TR><TR>
<TD WIDTH=40%>Date: December 1, 2000</TD><TD WIDTH=60%>F. Robert Merrill III
</TD></TR><TR><TD WIDTH=40%></TD><TD WIDTH=60%>Executive Vice President,
Finance</TD></TR><TR><TD WIDTH=40%></TD><TD WIDTH=60%>Chief Financial Officer
and Treasurer</TD></TR></TABLE>
<HR>
<P ALIGN=RIGHT><U><B>Exhibit 99.1</B></U></P>
<TABLE WIDTH=100% CELLPADDING=0 CELLSPACING=0>
<TR>
<TD WIDTH=75% ALIGN=LEFT><B>Agency Contact:</B></TD>
<TD WIDTH=25% ALIGN=LEFT><B>Company Contact:</B></TD></TR>
<TR>
<TD>Neil Berkman Associates</TD>
<TD>Chris Chavez</TD></TR>
<TR>
<TD>(310) 277-5162</TD>
<TD>President and CEO</TD></TR>
<TR>
<TD>info@BerkmanAssociates.com</TD>
<TD>(972) 309-8000</TD></TR></TABLE>
<P></P>
<P></P>
<H1 ALIGN=CENTER><FONT SIZE=3>Advanced Neuromodulation Systems To Acquire<BR>
Hi-tronics Designs, Inc.</FONT></H1>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DALLAS, TEXAS,  December 1,
2000 -- Advanced  Neuromodulation  Systems,  Inc. (ANS)(NASDAQ:ANSI) announced
today that it has agreed to acquire Hi-tronics Designs, Inc. (HDI), a privately
held contract developer and original equipment manufacturer (OEM) of
electro-mechanical medical devices headquartered in Budd Lake, New Jersey.
ANS will acquire all of HDI's outstanding stock through a merger in exchange
for 1.1 million shares of ANS' common stock.</P>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"This acquisition  provides
ownership of HDI's proprietary  technical design dossier and outstanding
research and development resources which should greatly enhance our ability to
accelerate new products to market. At the same time, it will  strengthen and
expand our capabilities as an OEM contract developer and supplier of advanced
electro-mechanical  medical  devices. ANS remains committed to serving existing
OEM customers and to strategically expanding our OEM customer base and related
portfolio of OEM products.</P>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"In addition to immediately
increasing our revenue base and bottom line, we anticipate some vertical
integration benefits in manufacturing that should enhance our gross margins.
It also broadens and strengthens our research and development capabilities by
allowing ANS to develop more sophisticated products in compressed,
development-cycle timetables," said Chris Chavez, president and chief executive
officer of ANS.</P>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noting that HDI developed and
will supply ANS' Totally Implantable Pulse Generator (IPG) and is the
manufacturer of ANS' transmitter used with its Renew&#153; stimulation system,
Chavez explained that HDI has developed more than 30 medical devices for leading
device companies, including Medtronic, Inc. (NYSE:MDT), Cyberonics
(NASDAQ:CYBX), Orthofix International N.V. (NASDAQ:OFIX), Exogen (now part of
Smith and Nephew plc) and Micromed Technology, Inc., and that it's technology
has been instrumental in the success of a number of new public medical device
companies. "HDI has developed cutting edge electro-mechanical devices in various
clinical applications, including cardiology, neurology and orthopedics. Its core
strength is in developing highly sophisticated electronic circuits with very low
power requirements utilizing both discreet and highly integrated technology.
This competency, when integrated with our own strengths in lead design and
packaging, will create a formidable research and development capability that
will benefit HDI's customers, as well as ANS' own product development efforts,"
Chavez added.</P>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ANS reported revenues of
$17.1 million through the first nine months of fiscal 2000. HDI's unaudited
estimated  revenues for fiscal 2000, which ended November 30, 2000, are $10.5
million, including  approximately $1.5 million of revenues associated with sales
to ANS. "Not only does this acquisition accelerate our strategic growth plans,
but it also is expected to be accretive to earnings on a fully diluted basis in
calendar year 2001," Chavez said.</P>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transaction is subject to
the receipt of all applicable regulatory approvals under the Hart-Scott-Rodino
Antitrust Improvements Act and other customary terms and conditions. The
transaction is expected to be accounted for on a "pooling of interests" basis
and should be completed by the end of calendar 2000. The Company expects to
record an acquisition-related charge for transaction related expenses this
quarter. In connection with the acquisition, the Board of Directors has
rescinded the share repurchase program under which 86,500 shares of common
stock remain authorized for purchase.</P>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Emphasizing that ANS is fully
committed to continuing to support HDI's existing  contract, development and
manufacturing business, Chavez said, "I am delighted that HDI's founders,
Anthony  Varrichio and William  Winstrom, who prior to founding HDI held
management  positions at  Intermedics and Biomet, Inc. (NASDAQ:BMET), will
continue in their current senior management positions. Their more than 45 years
of combined experience in developing implantable and non-implantable medical
devices will be an invaluable resource for us as we diversify our product
offerings and enhance our competitive position in order to participate in the
growing market for electrical stimulation products."</P>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Founded in 1987, HDI is a
privately held contract developer and original equipment manufacturer of
electro-mechanical medical devices headquartered in Budd Lake, New Jersey. Its
manufacturing facility in Hackettstown, New Jersey is ISO 9000 certified
and approved by the U.S. Food and Drug Administration (FDA). Approximately 100
employees work at HDI's two facilities. ANS expects to continue operating HDI's
business at these facilities under the continued leadership of Mr. Varrichio,
who will serve as an Executive Vice President of ANS and General Manager of HDI.
</P>
<P><B>About Advanced Neuromodulation Systems</B></P>
<P>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Advanced Neuromodulation
Systems designs, develops, manufactures and markets implantable systems used to
manage chronic intractable pain and other disorders of the central nervous
system.</P>

<P><B><I>The following is a &#147;safe harbor&#148; statement under the Private
Securities Litigation Reform Act of 1995:</I></B></P>
<P><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Statements contained in
this document that are not based on historical facts are &#147;forward-looking
statements.&#148; Terms such as &#147;plan,&#148; &#147;should,&#148;
&#147;would,&#148; &#147;anticipate,&#148; &#147;believe,&#148;
&#147;intend,&#148; &#147;estimate,&#148; &#147;expect,&#148;
&#147;predict,&#148; &#147;scheduled,&#148; &#147;new  market,&#148;
&#147;potential market applications&#148; and similar expressions are intended
to identify forward-looking statements. Such statements are by nature subject to
uncertainties and risks, including but not limited to:receipt of required
approvals; qualification of the proposed merger for pooling accounting
treatment; successful integration of HDI's business with the Company's and
recognition of anticipated merger benefits; completion of research and
development projects in an efficient and timely manner; obtaining regulatory
approvals on a timely and cost-efficient basis to permit the introduction of new
products; the successful reclassification of the IPG by the FDA; the
satisfactory completion of clinical trials and/or market tests prior to the
introduction of new products; the adequacy, acceptability and timeliness of
component supply; the approval of new products by reimbursement agencies like
insurance  companies, HMOs, Medicare and Medicaid; the efficacy of the Company's
and HDI's products for new applications; and other risks detailed from
time to time in the Company's SEC filings. Consequently, if such management
assumptions prove to be incorrect or such risks or uncertainties materialize,
anticipated results could differ materially from those forecast in
forward-looking statements.</I></P>
</BODY>
</HTML>

</TABLE>
</TEXT>
</DOCUMENT>
</SUBMISSION>
